Drug development cost pharma $2.2B per asset in 2024 as GLP-1s drive financial return
Fierce Biotech The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020, as reported in Deloitte’s annual report, “Measuring the return from pharmaceutical innovation.” In 2024, the average […]
read more
Adopting Flexible Strategies to Combat Capacity Shortages
Biopharm International In January 2025, Samsung Biologics signed a six-year, $1.4 billion contract manufacturing agreement with an as-yet undisclosed European pharmaceutical company, with production to take place at Samsung’s manufacturing site in Songdo, South Korea (1). Simultaneously, at the J.P. Morgan Healthcare Conference held in San Francisco, the company announced plans to complete construction of […]
read more
Prevention and Longevity: Shaping the Healthcare System of the Future – Free Registration
April 4, 2025 – Maison de la Chimie, Paris You are invited to the first edition of an annual event dedicated to preventive and longevity medicine—an unprecedented gathering of experts, decision-makers, and key players in the healthcare ecosystem. Held in a prestigious institutional venue, this event will explore the latest clinical results, ad hoc technological […]
read more
Demystifying the Complexity of Trials in Targeted Therapies – Free Registration
April 29, 2025 – 1:15 PM – 2:00 PM CEST (Webinar) Join our upcoming webinar in collaboration with PharmaLex to explore current challenges in clinical trials for targeted therapies. We’ll discuss how eClinical solutions can optimize processes from managing complex data to coordinating stakeholders and enabling real-time decision-making. This interactive session is designed for industry […]
read more